The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020

This section has no associated Explanatory Memorandum

156.  In regulation 202 (amendment of regulation 259 (packaging requirements: information for blind and partially sighted patients)), for “for “marketing authorisation” to the end substitute “for “marketing authorisation,” substitute “UK marketing authorisation, EU marketing authorisation”.”.